Drug Profile
TL 118
Alternative Names: Hamsa 1; TL-111; TL-112Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Tiltan Pharma
- Class Nonsteroidal anti-inflammatories; Sulfonamides
- Mechanism of Action Alkylating agents; Angiogenesis inhibitors; Histamine H2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer; Prostate cancer
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Pancreatic cancer (Metastatic disease, Adjuvant therapy) in Israel, Israel, USA (PO)
- 06 Oct 2017 TL 118 is still at phase II development stage for Pancreatic cancer (Adjuvant therapy, Metastatic disease) in Israel and USA (PO,suspension) (Tiltan Pharma website, October 2017)
- 06 Oct 2017 No recent reports on development identified - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in Israel (PO,suspension)